跳转至内容
Merck
CN

A2729

氨磺必利

≥98% (HPLC), D2/D3 dopamine receptor antagonist , powder

别名:

4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxybenzamide, DAN-2163, Deniban

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C17H27N3O4S
化学文摘社编号:
分子量:
369.48
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
275-831-7
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

氨磺必利, ≥98% (HPLC)

InChI

1S/C17H27N3O4S/c1-4-20-8-6-7-12(20)11-19-17(21)13-9-16(25(22,23)5-2)14(18)10-15(13)24-3/h9-10,12H,4-8,11,18H2,1-3H3,(H,19,21)

InChI key

NTJOBXMMWNYJFB-UHFFFAOYSA-N

SMILES string

O=C(NCC1CCCN1CC)C2=CC(S(=O)(CC)=O)=C(N)C=C2OC

assay

≥98% (HPLC)

form

powder

storage condition

desiccated, protect from light

color

white

originator

Sanofi Aventis

storage temp.

2-8°C

Quality Level

正在寻找类似产品? 访问 产品对比指南

Application

Amisulpride has been used as a dopamine receptor inhibitor to study its effects on diabetic bone abnormalities in mice.

Biochem/physiol Actions

Amisulpride is a highly selective D2/D3 dopamine receptor antagonist and atypical antipsychotic.
Amisulpride is a substituted benzamide derivative. It has a higher affinity towards dopamine receptors in limbic structures than the striatal structures. Amisulpride has a therapeutic effect against schizophrenia.

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

J Peuskens et al.
Psychiatry research, 88(2), 107-117 (2000-01-06)
Amisulpride, a substituted benzamide with high selectivity for dopamine D3 and D2 receptors, was compared with the antipsychotic risperidone in patients with acute exacerbations of schizophrenia. The study was double-blind and involved 228 patients allocated, after a 3-6-day wash-out period
Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia
Peuskens J, et al.
Psychiatry Research, 88(2), 107-117 (1999)
Impaired gastric hormone regulation of osteoblasts and lysyl oxidase drives bone disease in diabetes mellitus
Daley E J, et al.
JBMR plus, 3(10), e10212-e10212 (2019)
Eileen J Daley et al.
JBMR plus, 3(10), e10212-e10212 (2019-11-07)
Diabetic bone disease is a complication of type I and type II diabetes, both of which are increasing in the United States and elsewhere. Increased hip and foot fracture rates do not correlate well with changes in bone mineral density
Ann Mortimer et al.
International clinical psychopharmacology, 19(2), 63-69 (2004-04-13)
Atypical antipsychotics offer advantages over earlier drugs for the treatment of schizophrenia, although few data exist on the relative merits of different atypical antipsychotics. A multicentre, double-blind, randomized trial was performed to compare amisulpride and olanzapine in the treatment of

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持